Ermenegildo Zegna N.V. (ZGN) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Since a changing ea ...

BILL Holdings (BILL) closed the last trading session at $45.28, gaining 0.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $66.75 indicates a 47.4% upside potential.The mean estimate comprises 24 short-term price targets with a standard deviation of $20.19. While the lowest estimate of $40.00 indicates a 11.7% decline from the current price level, the most optimistic analyst expe ...

Vigil Neuroscience, Inc. (VIGL) closed the last trading session at $7.93, gaining 0.6% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $10 indicates a 26.1% upside potential.The average comprises seven short-term price targets ranging from a low of $8.00 to a high of $22.00, with a standard deviation of $5.29. While the lowest estimate indicates an increase of 0.9% from the current ...

Core Viewpoint - The article discusses the reliability of Wall Street analysts' recommendations, particularly focusing on Halliburton (HAL), and emphasizes the importance of using these recommendations in conjunction with other analytical tools for making investment decisions [1][5]. Group 1: Halliburton's Brokerage Recommendations - Halliburton has an average brokerage recommendation (ABR) of 1.74, indicating a position between Strong Buy and Buy, based on recommendations from 27 brokerage firms [2]. - Out of the 27 recommendations, 16 are classified as Strong Buy, accounting for 59.3%, while 2 are classified as Buy, making up 7.4% of the total recommendations [2]. Group 2: Limitations of Brokerage Recommendations - Solely relying on brokerage recommendations may not be advisable, as studies indicate they often fail to guide investors effectively towards stocks with high potential for price appreciation [5]. - Analysts from brokerage firms tend to exhibit a strong positive bias in their ratings, with five "Strong Buy" recommendations for every "Strong Sell" recommendation, which may mislead investors [6][10]. Group 3: Zacks Rank vs. ABR - The Zacks Rank is a proprietary stock rating tool that classifies stocks into five groups based on earnings estimate revisions, providing a more reliable indicator of near-term price performance compared to ABR [8][11]. - Unlike ABR, which is based solely on brokerage recommendations, the Zacks Rank is updated frequently to reflect changes in earnings estimates, making it a timely tool for predicting future price movements [12]. Group 4: Current Earnings Estimates for Halliburton - The Zacks Consensus Estimate for Halliburton's current year earnings has declined by 1.2% over the past month to $2.37, indicating growing pessimism among analysts regarding the company's earnings prospects [13]. - This decline in earnings estimates has resulted in a Zacks Rank of 4 (Sell) for Halliburton, suggesting caution despite the Buy-equivalent ABR [14].

Core Viewpoint - The article discusses the reliability of brokerage recommendations, particularly focusing on Oneok Inc. (OKE), and emphasizes the importance of using these recommendations in conjunction with other analytical tools like the Zacks Rank for making informed investment decisions [1][5][10]. Brokerage Recommendations - Oneok has an average brokerage recommendation (ABR) of 1.65, indicating a consensus between Strong Buy and Buy, based on recommendations from 17 brokerage firms [2][4]. - Out of the 17 recommendations, 11 are Strong Buy and 1 is Buy, which account for 64.7% and 5.9% of all recommendations, respectively [2]. Limitations of Brokerage Recommendations - Studies indicate that brokerage recommendations have limited success in guiding investors towards stocks with the best price increase potential [5]. - Analysts often exhibit a positive bias due to the vested interests of brokerage firms, leading to a disproportionate number of favorable ratings compared to negative ones [6][10]. Zacks Rank as an Alternative - The Zacks Rank is presented as a more reliable indicator of a stock's near-term price performance, based on earnings estimate revisions rather than brokerage recommendations [8][11]. - The Zacks Rank is updated more frequently and reflects the latest earnings estimates, making it a timely tool for predicting future price movements [12]. Current Earnings Estimates for Oneok - The Zacks Consensus Estimate for Oneok's current year earnings remains unchanged at $5.23, suggesting stability in analysts' views regarding the company's earnings prospects [13]. - Due to the unchanged consensus estimate and other factors, Oneok holds a Zacks Rank of 3 (Hold), indicating a cautious approach despite the Buy-equivalent ABR [14].

Core Viewpoint - CF Industries (CF) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Performance - The Zacks rating system is based on changes in a company's earnings picture, with the Zacks Consensus Estimate reflecting EPS estimates from sell-side analysts [1][2]. - The correlation between earnings estimate revisions and stock price movements is strong, with institutional investors using these estimates to determine fair value [4][6]. - For CF, the recent increase in earnings estimates suggests an improvement in the company's underlying business, likely leading to higher stock prices [5][10]. Earnings Estimate Revisions for CF - CF is projected to earn $6.82 per share for the fiscal year ending December 2025, showing no year-over-year change [8]. - Over the past three months, the Zacks Consensus Estimate for CF has increased by 10%, indicating a positive trend in earnings expectations [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 (Strong Buy) stocks historically generating an average annual return of +25% since 1988 [7]. - The upgrade of CF to a Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting a strong potential for market-beating returns in the near term [9][10].

Red Robin (RRGB) closed the last trading session at $5.00, gaining 57.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $9.38 indicates an 87.6% upside potential.The average comprises four short-term price targets ranging from a low of $3.50 to a high of $12.00, with a standard deviation of $3.94. While the lowest estimate indicates a decline of 30% from the current price level, t ...

Shares of Brainsway Ltd. Sponsored ADR (BWAY) have gained 7.1% over the past four weeks to close the last trading session at $11.49, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $15.05 indicates a potential upside of 31%.The average comprises four short-term price targets ranging from a low of $14.20 to a high of $16.00, with a standard deviation of $0.74. While the lowest es ...

AMN Healthcare Services (AMN) closed the last trading session at $21.18, gaining 2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $27.39 indicates a 29.3% upside potential.The average comprises seven short-term price targets ranging from a low of $24.00 to a high of $33.00, with a standard deviation of $3.88. While the lowest estimate indicates an increase of 13.3% from the curre ...

Galena Biopharma, Inc. (SLS) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system ...